Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for November 2012
November 1, 2012
- FibroGen to Present Phase 2 Data for FG-4592, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), at American Society of Nephrology (ASN) Kidney Week 2012
- Genzyme Announces Publication of LEMTRADA (alemtuzumab) Pivotal Studies in The Lancet
- Sanofi and Regeneron Announce Publication of Phase 2 Results with LDL Cholesterol-Lowering PCSK9 Antibody in the New England Journal of Medicine
- Aeterna Zentaris to Present Proof of Concept for Disorazol Z Cytotoxic Conjugates such as AEZS-125 in Ovarian Cancer Mouse Model at Upcoming ENA Symposium
- Genzyme Announces Publication of Lemtrada (alemtuzumab) Pivotal Studies in The Lancet
- Aerie Pharmaceuticals Announces Positive Phase 2a Clinical Results for a Fixed Combination of its Rho Kinase Inhibitor, AR-12286, with Travoprost for the Treatment of Glaucoma
- Meth Vaccine Shows Promising Results in Early Tests
- Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
- Concert Pharmaceuticals Presents Preclinical Results Demonstrating CTP-499, a Novel Treatment for Diabetic Kidney Disease, Ameliorated Renal Fibrosis and Inflammation In Vivo
- Cyclacel Announces Publication of Phase 2 Results for Sapacitabine in Elderly AML Patients in the Lancet Oncology
- Inotek Pharmaceuticals to Present Phase 2 Data of Trabodenoson in Glaucoma at the Ophthalmology Innovation Summit
November 2, 2012
- Affymax and Takeda Announce Analyses from OMONTYS (peginesatide) Injection Phase 3 Dialysis Studies Presented at 2012 American Society of Nephrology Meeting
- Advaxis Updates Phase 2 Cervical Cancer Trial Data
- Biogen Idec and Sobi Announce Positive Top-Line Results from Phase 3 Study Investigating Long-Lasting Recombinant Factor VIII Fc Fusion Protein in Hemophilia A
- Bristol-Myers Squibb and Pfizer Announce New Data on Stroke Prevention in Atrial Fibrillation to be Presented at American Heart Association 2012 Scientific Sessions
- Gilead's Once-Daily Novel Prodrug for the Treatment of HIV Meets 24-Week Primary Objective in Phase 2 Study
- Aerie Pharmaceuticals Announces Positive Phase 2a Clinical Results for its Novel, Dual Mechanism Compound, AR-13324, for the Treatment of Glaucoma
- Amgen To Present Data From Four Phase 2 Studies At Upcoming American Heart Association Scientific Sessions 2012
- Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
- Advantages of Pressure BioSciences' PCT Platform Highlighted at a Recent International Scientific Conference Focused on the Role of Proteins in the Cause, Prevention, and Treatment of Disease
- Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
- Six Late-breaking Abstracts Selected for Oral Presentation at The Liver Meeting
- Genkyotex's NOX Inhibitor GKT137831 Phase I Data Presented at Kidney Week 2012
- Karyopharm Therapeutics Announces Multiple Publications on Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in Cancer
- EnVivo Pharmaceuticals Presents Additional EVP-6124 Phase 2b Clinical Trial Results at the Clinical Trials on Alzheimer's Disease (CTAD) Meeting
November 5, 2012
- RE-LY Sub-Analysis Suggests Similar Safety and Efficacy With Pradaxa (dabigatran etexilate mesylate) Versus Warfarin in NVAF Patients With and Without Diabetes
- New Clinical Trial Data Show Substantial Improvement with Eculizumab (Soliris) in Patients with STEC-HUS
- Two-Year Data Show Long-Term Benefits of Chronic Soliris Therapy in Patients with aHUS
- BioMarin Phase 3 Study of GALNS for the Treatment of MPS IVA Meets Primary Endpoint
- Raptor Pharmaceutical Corp. Announces Positive Data on RP103 Extension Study Presented at Kidney Week 2012
- Phase 3 Sensipar/Mimpara EVOLVE Trial Published In The New England Journal Of Medicine
- Otsuka's Investigational Compound for Autosomal Dominant Polycystic Kidney Disease (ADPKD), Tolvaptan, Meets Primary Endpoint in a Phase III Clinical Trial
- Omeros' Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
- Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
- Hypertensive Acute Heart Failure Study Results to Be Presented at American Heart Association Scientific Sessions 2012
- Addex Reports Top-line Data from a Successful Phase 2a Clinical Study with ADX71149 in Schizophrenia Patients
- Poxel's Anti-diabetic Imeglimin Shows Significant Clinical Benefits in Type 2 Diabetes when Added to Sitagliptin
- Roche?s Aleglitazar Renal Safety Study Alenephro Meets Primary Endpoint
- Comparison of Anti-Clotting Drugs Finds Differences in Platelet Reactivity, Similar Clinical Outcomes
- FDA Mini-Sentinel Assessment Reinforces Safety Data of Pradaxa (dabigatran etexilate mesylate)
- Infinity to Present IPI-145 Phase 1 Clinical Data at ASH
- YM BioSciences JAK Inhibitor CYT387 Produces Meaningful Reductions of Splenomegaly and Durable Transfusion Independence Responses
- Novel Apolipoprotein A-I Therapy, CSL112, May Represent New Option for Reducing Recurrent Heart Attack Risk, Early CSL Studies Show
- MorphoSys and Xencor Report Clinical Data for MOR208/XmAb5574
- FibroGen Reports Data from Phase 2 Study of FG-4592 Hemoglobin Correction and Maintenance in End-Stage Renal Patients
- FibroGen Announces Results Showing That FG-4592, An Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI), Corrects Anemia Without Intravenous Iron Supplementation in Incident Dialysis Patients
- Early use of antiviral medications may help prevent lung failure in children with the flu
- Array BioPharma To Present Clinical Data At The 2012 ASH Meeting On ARRY-520, A KSP Inhibitor, And ARRY-614, A Dual p38/Tie2 Inhibitor
- VELCADE (bortezomib), ADCETRIS (brentuximab vedotin) and Millennium Pipeline Agents to be Featured at American Society of Hematology Annual Meeting
- Celldex Announces Upcoming Data Presentation at the American Society of Hematology 54th Annual Meeting and Exposition
- Emergent BioSolutions Announces Acceptance of TRU-016 and Bispecific Abstracts for Presentation at 2012 American Society of Hematology Annual Meeting
- Seattle Genetics' ASH 2012 Presentations Highlight ADCETRIS and Demonstrate Leadership in the Development of Antibody-Drug Conjugates (ADCs)
November 6, 2012
- VAP Lipid Panel Helps Predict Heart Attack Risk and Improved Outcomes in African Americans
- Kamada Announces New Data on its Glassia Drug Supporting its Diabetes Activities and Treatment of Additional Therapeutic Indications
- Emergency Hypertensive Acute Heart Failure Study PRONTO Demonstrates Clevidipine Superior to Standard of Care
- Omthera Pharmaceuticals Presents Successful Phase 3 Results from EVOLVE and ESPRIT Clinical Studies for Epanova; Both Trials Meet Primary and Secondary Endpoints
- MorphoSys to Present Clinical Data on MOR103 at 2012 American College for Rheumatology Annual Meeting
- Isotechnika Pharma's NICAM Portfolio Demonstrates Positive Anti-Viral Activity Against Several Important Viruses
- Circulation Publishes Results From RUTHERFORD Study Which Showed AMG 145 Significantly Reduced LDL Cholesterol In Patients With Heterozygous Familial Hypercholesterolemia
- Therapy With Bone Marrow-Derived Stem Cells Does Not Improve Short-Term Recovery After Heart Attack
- AMAG Pharmaceuticals, Inc. Announces that Feraheme Abstracts for the American Society of Hematology Annual Meeting are Now Available
- "Good" Cholesterol Drug Doesn?t Reduce Risks in Heart Patients
- MEI Pharma Reports New Data Showing High Response Rates in Clinical Trial of Pracinostat and Azacitidine in Myelodysplastic Syndrome
- LX4211 Phase 2b Results Presented At American Heart Association Annual Conference
- SCYNEXIS to Report Phase 2a Study of SCY-635 for Treatment of HCV at AASLD
- Chelsea Therapeutics Announces Results From Northera(TM) (droxidopa) Study in Spinal Cord Injury at the 23rd International Symposium on the Autonomic Nervous System
- Positive Results from Phase 1/2 POSEIDON Trial Demonstrate Donor (Allogeneic) Adult Mesenchymal Stem Cells (MSCs) Utilizing BioCardia Catheter Delivery System Are Similarly Effective as Patients' Own Stem Cells in Treating Ischemic Heart Failure
- FibroGen Reports Data from Phase 2 Study of FG-4592
- Cleveland BioLabs Announces Publication of Studies on Effect of Entolimod (CBLB502) on Graft-Versus-Tumor Activity in Models of Allogeneic Bone Marrow Transplantation
- Array BioPharma To Present Clinical Data On ARRY-797 At The 2012 American College Of Rheumatology Annual Meeting
- ALS Association-Funded Study Finds Blood Protein May Serve as Biomarker to Measure ALS Decline
- The Use of New Replikins Synthetic Vaccines to Prevent Pandemics to be Presented at Influenza Congress Nov. 12 in Washington DC
- Dr. Donders' Vulvodynia Study Published in Journal of Lower Genital Tract Disease
- The Lancet Publication Of LAPLACE-TIMI 57 And MENDEL Studies Showed AMG 145 Significantly Reduced LDL Cholesterol
November 7, 2012
- Novartis Phase III Study Shows RLX030 Improved Symptoms and Reduced Deaths by One-Third in Patients with Acute Heart Failure
- Santarus and Pharming Announce Positive Top-Line Phase III Results for Ruconest in Acute Hereditary Angioedema
- Interim Results of the Phase 2b GALAXY Trial to be Presented at the Chemotherapy Foundation Symposium
- Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
- Improved Heart Disease Risk Assessment Achieved in At-Risk and Hidden-Risk Populations With VAP® Lipid Panel
- Arisaph Pharmaceuticals Reports Positive Results From Two Safety Clinical Trials For Its Niacin Analog (ARI-3037MO)
- Poor Control of Anticoagulant Therapy Leads to Increased Adverse Events for Patients with Atrial Fibrillation (AF)
- Repeat Dosing of Smt C1100 for Treatment of Duchenne Muscular Dystrophy Meets Endpoints in Phase 1 Clinical Trial
- Octapharma Sponsors Educational Programs, Presents Research at the 64th Annual NHF Meeting in Orlando
- Depomed Reports Top Line Data for Phase 2 Study in Parkinson's Disease
- Researchers to Present Additional Data on Soliris (eculizumab) as a Treatment for Patients with PNH and aHUS at ASH Annual Meeting
November 8, 2012
- Omeros to Present Data from Successful OMS302 Phase 3 Clinical Trial at the American Academy of Ophthalmology Annual Meeting
- Inotek Pharmaceuticals Presents Positive Phase 2 Data of Trabodenoson in Glaucoma
- Advanced Cell Technology Announces Interim Data from Its Three Ongoing Macular Degeneration Trials
- Iconic Therapeutics Announces Phase 1 Wet AMD Study Results
November 9, 2012
- Phase 3 Results Show Canagliflozin as Add-On Therapy to Metformin and Pioglitazone Significantly Lowers Blood Sugar Levels in Adult Patients with Type 2 Diabetes
- Phase III Data for Teva's QNASL (beclomethasone dipropionate) Demonstrate Efficacy Profile in Pediatric Patients with Seasonal Allergic Rhinitis
- RTS,S Malaria Candidate Vaccine Reduces Malaria by Approximately one-third in African Infants- Results from Ongoing Phase III Clinical Trial Announced
- New Data From UCB's Immunology Portfolio Highlighted at 2012 American College of Rheumatology Meeting
- Verastem Reports Data on Focal Adhesion Kinase Program at the 2012 EORTC Symposium on Molecular Targets and Cancer Therapeutics
- Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
- Interim Data on GenSpera's G-202 Presented at Symposium on Molecular Targets and Cancer Therapeutics
- OncoMed Pharmaceuticals Announces Presentations of Anti-Notch2/3 and Demcizumab Clinical Data at EORTC-NCI-AACR Meeting
- ProNAi Expands Management Team and Presents Encouraging Phase I Study Results for Lead Cancer Drug at Cancer Meeting
- Oncolytics Biotech Inc. Collaborators Present Positive REOLYSIN Trial Results and Research at EORTC-NCI-AACR Symposium
- Plexxikon Announces Three-Year Survival in Zelboraf-Treated Metastatic Melanoma Patients
November 12, 2012
- Investigational Hepatitis C Dual DAA Regimen of Daclatasvir and Asunaprevir Achieved SVR12 in 78% of Difficult-to-Treat Genotype 1b Prior Null Responders In Expanded Phase II Study
- Investigational Hepatitis C Quad Therapy Regimen of Daclatasvir and Asunaprevir Plus Interferon Alfa and Ribavirin Achieved SVR24 in 93% of Difficult-to-Treat Genotype 1a/b Prior Null Responders in Expanded Phase II Study
- BioCryst Broad-Spectrum Antiviral BCX4430 Highly Effective against Yellow Fever in a Preclinical Disease Model
- Merck Presents Early-Stage Interim Data for MK-3475, an Investigational Therapy for the Treatment of Advanced Melanoma
- CellAct Pharma's Topoisomerase Inhibitor Demonstrates Success in Phase I Study Involving Adults with Heavily Pretreated Solid Tumors
- Clovis Oncology Announces Negative Outcome of CO-101 in Pivotal LEAP Pancreatic Cancer Study
- SCYNEXIS' Oral SCY-635 Shows Potential as an Immune Acting Antiviral to Augment Current HCV Treatments
- Abbott Presents Promising Phase 2b Interferon-free Hepatitis C Results at 2012 Liver Meeting(R)
- Phase 2 Results Show Incivo (telaprevir), in Combination With Peginterferon Alfa and Ribavirin, is Effective in Treating Patients Co-infected With Genotype-1 Chronic Hepatitis C Virus and HIV
- Gilead Announces 100 Percent Sustained Virologic Response Rate (SVR4) for an Interferon-Free Regimen of Sofosbuvir (GS-7977), GS-5885 and Ribavirin in Treatment-Naïve Genotype 1 Hepatitis C Infected Patients
- Data from Viral Kinetic Study Showed Rapid Reduction of HCV RNA with ALS-2200 (VX-135), Vertex's Oral Nucleotide Analogue in Development for the Treatment of Hepatitis C
- ADACTA Study Showed Actemra Improved Signs and Symptoms of Rheumatoid Arthritis Significantly More Than Adalimumab as a Single-Agent Therapy
- Ensemble Therapeutics Presents Oral Efficacy of First-in-Class Small Molecule Targeting IL-17 for Inflammation in Preclinical Studies
- Efficacy and Safety Data from Phase 2B Trials of Janssen's Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
- Phase 2b Data of Boehringer Ingelheim's Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
- AstraZeneca Announces Top-line Phase III Results from Naloxegol Pivotal Trials In Patients With Opioid-Induced Constipation
- Interim Phase II Data of Merck's Investigational MK-5172 in Combination Therapy in Chronic Hepatitis C Virus Genotype 1 Infection to be Presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting/
- Vertex Presents New Phase 3 Data that Showed People with Hepatitis C Treated with Twice-Daily Telaprevir Achieved Viral Cure (SVR12) Rates Similar to Those Treated Three Times Daily
- Abbott Announces First Long-term Patient-reported Health Outcomes Data for Investigational Use of HUMIRA(R) (Adalimumab) in Patients with Active Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
- Novartis new two-year data with Certican shows positive outcomes at 24 months in largest liver transplant trial to date
- Achillion Provides Update on Clinical HCV Development Programs
- Merck Reports New Phase III Analyses on Anemia Management Strategies Used With Victrelis (Boceprevir) Combination Therapy, Including Cirrhotic Patients
- MorphoSys Reports Successful Phase 1 Study of MOR103 Using a Subcutaneous Administration
- GI-5005 Improves Virologic Clearance of HCV in Combination with PegIFN/Ribavirin in IL28B T/T Patients
- Novartis data show ACZ885 delivered rapid and strong symptom relief while reducing frequency of attacks in two periodic fever syndromes
- GLPG0634 single center Proof of Concept results to be presented at American College of Rheumatology Annual meeting
- HALT-HE Study Underscores Role of Ammonia in Hepatic Encephalopathy
November 13, 2012
- Santarus and VeroScience Announce Publication of New Analysis of CYCLOSET (bromocriptine mesylate) Cardiovascular Data in the Journal of the American Heart Association
- Long-Term Efficacy and Safety Results of Epratuzumab in Lupus Presented at Rheumatology Conference
- RAPID-axSpA study showed certolizumab pegol reduced signs and symptoms of axial spondyloarthritis
- ViroPharma's Cinryze (C1 Esterase Inhibitor [Human]) Prophylaxis Study Showed Safety Data of Escalating Doses in Patients With Hereditary Angioedema
- New Phase 3 Findings Show Stelara Significantly Reduced Signs and Symptoms of Active Psoriatic Arthritis
- Antares Pharma Announces Positive Results from Final MTX Medi-Jet Clinical Study
- Preliminary Findings From Rheumatoid Arthritis Patient Survey Reveal Strong Interest in Needle-Free Self-Injection
- New Data Supporting Use of EXPAREL via Infiltration into the Transversus Abdominis Plane Presented at 11th Annual American Society of Regional Anesthesia and Pain Medicine Meeting
- MediciNova Announces Publication of MN-221 Clinical Results in Journal of Asthma
- New Canadian-Led Global Study of Bayer's Xarelto (rivaroxaban tablet), Initiated for the Secondary Prevention of Cardiovascular Death, Myocardial Infarction and Stroke in Patients with Coronary or Peripheral Artery Disease
- New Data Demonstrate Krystexxa-Treated Refractory Chronic Gout Patients Experienced Significantly Improved Health-Related Quality of Life
- Ligand Announces Positive Preclinical Data on HepDirect Liver-Targeted Antiviral for the Treatment of Hepatitis C
- Oral Apremilast Achieves Statistical Significance for the Primary Endpoint of ACR20 in the First Phase III Study (PALACE-1) in Patients with Psoriatic Arthritis
- Anthera Announces Additional Data from the Phase 2b PEARL-SC Presented at the ACR/ARHP 2012 Annual Scientific Meeting
- Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
- UCB Announces Data on Cimzia (certolizumab pegol) for Patients with Moderate to Severe Rheumatoid Arthritis at American College of Rheumatology 2012 Congress
November 14, 2012
- OncoSec Medical Reports Positive Interim Efficacy Results from Phase IV Study of NeoPulse in Skin Cancer Patients
- PaxVax Presents Phase 1 Clinical Trial Data for Single-Dose Cholera Vaccine
- New Data on NovoTTF Therapy to be Presented at the 2012 SNO Meeting
- First Effective Treatment For Traumatic Brain Injury Reported by Institute of Neurological Recovery, Even Years After Injury
November 15, 2012
- OncoSec Medical Reports Positive Preliminary Efficacy Results from Phase II Study of ImmunoPulse in Metastatic Melanoma Patients
- Gilead's Once-Daily Single Tablet Regimen StribildTM Maintains High Viral Suppression Through Two Years of Therapy Among Treatment-Naïve HIV Patients
- Gilead's Complera Non-Inferior to Atripla Among Treatment-Naïve HIV Patients
- Gilead's Once-Daily Single Tablet Regimen Stribild Maintains High Viral Suppression Through Two Years of Therapy Among Treatment-Naïve HIV Patients
- RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers
- RXi Pharmaceuticals Announces Pharmacokinetic Results of its Single Dose Phase 1 Study with RXI-109 in Healthy Volunteers
- POZEN Announces Positive Results for the PA8140-102 Bioavailability Study
- Celldex Therapeutics Announces Positive Three-Year Survival Data for Rindopepimut Phase 2 Clinical Program
November 16, 2012
- DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
- Tranzyme Pharma Announces Top-Line Results of TZP-102 Phase 2b Trial
- ADAPTIMMUNE: Investigators to Present Preliminary Findings for Adaptimmune?s Gene Engineered T Cells in Myeloma at the Annual American Society of Hematology Meeting on Monday 10 December
- Pfizer Reports Top-Line Results Of A Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation As Adjunctive Treatment In Adult Patients With Partial Onset Seizures
- CytRx's Aldoxorubicin Clinical Data Presented at Connective Tissue Oncology Society (CTOS) 7th Annual Meeting in Prague, Czech Republic
- Scottsdale Healthcare, TGen physicians lead worldwide study of new drug regimen for patients with pancreatic cancer
- AcelRx Announces Primary Endpoint Met in Phase 3 Non-Inferiority Study of Sublingual Sufentanil NanoTab PCA System vs. IV PCA Morphine for Post-Operative Pain
- AcelRx Announces Achievement of the Primary End-Point in Phase 3 Comparative Study Involving the Sufentanil NanoTab PCA System and Plans to Hold a Conference Call and Webcast Tomorrow to Discuss Top-Line Results
November 19, 2012
- Genentech Study Showed That Avastin Helped People with Newly Diagnosed Glioblastoma Live Longer without Their Disease Worsening When Added to Radiation and Chemotherapy
- Top Researchers Present Promising Bendavia Findings at Annual American Society of Nephrology Meeting
- Aeterna Zentaris: Data Demonstrate that Perifosine Combined with Temsirolimus Was Well Tolerated in Phase 1 Trial in Malignant Glioma
- Bio-Path Holdings Successfully Completes Fourth Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia
- UK Scientists Report on Efficacy of Aradigm's Lipoqui Against Pneumonic Plague
- Nature Biotechnology Study Highlights New Myelin Specific Approach to Treat Multiple Sclerosis
November 20, 2012
- New Data Demonstrate Reduction in Opioid Use, Hospital Cost and Length of Stay with EXPAREL as the Foundation of a Multimodal Regimen
- Modified Citrus Pectin Protects Against Vascular Hardening
- Atox Bio Announces Positive Top Line Results in the AB103 Necrotizing Soft Tissue Infections (NSTI) Phase 2a Trial
- Astex Pharmaceuticals Announces Oral Presentation of SGI-110
- A Single Dose of Medicago's H5N1 VLP Vaccine Protects Against Additional Pandemic Flu Strains in a Preclinical Study
- Acetylon Pharmaceuticals' Selective HDAC Inhibitor Programs to be Featured at the 54th Annual Meeting of the American Society of Hematology
- XBiotech Reports Positive Phase II Interim Analysis Results in Vascular Disease
November 21, 2012
November 26, 2012
- Researchers Discover Gender-based Differences in Alzheimer's Disease
- Data Published in Nature Biotechnology Show Messenger (m)RNA Prophylactic Vaccines Based on CureVac's RNActive Technology Demonstrate Immunogenicity and Protection Against Influenza Virus Infection
- Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
- OneMedPlace Releases Update to Research Report on Amarantus Biosciences Focused on New Positive Ischemic Heart Disease Efficacy Data for MANF in Animals
- EntreMed Announces Publication Of Preclinical Results For ENMD-2076 In Triple-negative Breast Cancer
- Drs. Hani Sabbah, David Brown, Sharon Hale and Robert Kloner Present Bendavia Research At 2012 American Heart Association Annual Meeting
- Interim Results of the Phase 2b/3 GALAXY Trial to be Presented at the Fifth Asia Pacific Lung Cancer Conference
- Aeterna Zentaris: Final Phase 2 Data for Perifosine in Lymphomas to be Presented at Upcoming ASH Meeting
- MetaStat Announces the Online Publication of Research Paper in Breast Cancer Research
- Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek Data at Upcoming Scientific Meetings
- Emerging Data on USL261 (Intranasal Midazolam) to Be Presented at the 66th Annual Meeting of the American Epilepsy Society
- ACADIA Pharmaceuticals to Host Conference Call and Webcast on November 27, 2012 at 8:00 AM EST to Present Top-Line Results from Its Pivotal Phase III Pimavanserin Parkinson's Disease Psychosis Trial
- Valeant Pharmaceuticals Announces Publication of Efinaconazole Phase III Results
November 27, 2012
- Intellipharmaceutics Announces Results of Initial Phase I Clinical Trial of Controlled-Release Pregabalin and Product Updates
- Amarantus BioSciences Announces Positive Data for MANF in Delivery Diffusion Animal Model of Parkinson's Disease
- ACADIA Announces Pimavanserin Meets Primary and Key Secondary Endpoints in Pivotal Phase III Parkinson's Disease Psychosis Trial
- Publication of two pivotal Phase III studies of regorafenib: Positive Phase III Data on Bayer's Regorafenib in Metastatic Colorectal Cancer (mCRC) and Gastrointestinal Stromal Tumor (GIST) Published in The Lancet
- Gilead Announces Sustained Virologic Response Rate of 78% From Phase 3 Study of Sofosbuvir for Genotype 2/3 Hepatitis C Infected Patients
- Research Published in European Journal of Pharmacology Shows that Star Scientific's Anatabine Suppresses Brain Inflammation in Animal Model of Alzheimer's Disease and in Blood
- AesRx to Present Phase 1 Data on Anti-Sickling Agent Aes-103 at ASH
- Pharming Announces Receipt Of US$10 Million Milestone Payment
November 28, 2012
- Discovery Labs Presents New SURFAXIN and AFECTAIR Data at 2012 Hot Topics in Neonatology Annual Meeting
- VivaGel phase 3 study results
- The Myelin Repair Foundation to Present at Partnering for Cures 2012
- KYTHERA Biopharmaceuticals Announces Results from Open-Label Study for ATX-101
November 29, 2012
- RBCC JV Target Amarantus Presents Parkinson's Therapeutic at CNS Summit
- Women for Positive Action Highlight Ongoing Need for More Research Into Gender Differences in HIV Outcomes
- Epizyme In Vivo Data Shows Promise in Personalized Therapeutics Programs for Acute Leukemia and Lymphoma
- Pfizer to Present Clinical Data from Its Hematology Portfolio at the 54th Annual Meeting of the American Society of Hematology
- NPS Pharmaceuticals Announces Publication of Pivotal Phase 3 Study of Gattex (teduglutide) in Short Bowel Syndrome-Intestinal Failure Patients
